Professor Filippi Andrea Riccardo

Doctor

Contacts

Mail: andreariccardo.filippi@istitutotumori.mi.it
Tel: 0223903832

Specialty / Department

Radiation oncology

Professor Andrea Riccardo Filippi is the Head of the Radio-Oncology Unit at Istituto Nazionale dei Tumori, Milan. He graduated in Medicine and Surgery from the University of Turin in 1998 and specialized in Radiation Oncology at the same university in 2002. Throughout his academic and professional journey, he has enhanced his training with international experiences, including a visiting fellowship at the Department of Radiation Oncology at Stanford University and the Gustave Roussy Institute in Paris. He is also an Associate Professor of Radiotherapy at the University of Milan's Department of Oncology.

Professor Filippi's extensive experience and expertise in the field of Radiation Oncology are recognized internationally, as demonstrated by his involvement in scientific committees and commissions of prominent societies, such as ESTRO (European Society for Radiotherapy and Oncology), IASLC (International Association for the Study of Lung Cancer), and ESMO (European Society for Medical Oncology), among others. He has actively contributed to research and development in many projects, mainly focused on lung cancer and hematological malignancies. He participates in conferences and collaborates with prestigious institutions worldwide. Moreover, he is the Coordinator of the Radiotherapy Commission of the Italian Lymphoma Foundation (FIL).

ORCID Publications

He has been or currently is the Principal Investigator of the following clinical trials:

DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, Stage III NSCLC ineligible for chemotherapy. International Study Coordinator/International PI. Sponsor: ASTRA ZENECA.
DEDALUS: An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypo-fractionated RT and maintenance immunotherapy for stage III unresectable NSCLC. Academic study sponsor: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (externally supported by ASTRA ZENECA)
BLUE SKY RADIOMICS: Observational Study on Computed Tomography as an Image-based Predictive Marker of Response to Chemoradiation Followed by Durvalumab in Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC). Academic study sponsor: Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
AUSTRAL: An open-label, multicenter, phase II study of radiotherapy followed by durvalumab and ceralasertib (AZD6738) in stage III NSCLC patients with thoracic relapses +/- oligometastases after PACIFIC regimen (externally supported by AstraZeneca)
GAZEBO: An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early-stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi (co-PI with prof. A. Pulsoni). Academic study sponsor Fondazione Italiana Linfomi (externally supported by Hofmann-La Roche Global, Switzerland).

He is a member of the International Steering Committees of the following studies:

RAFTING: Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after two chemotherapy cycles. (Sponsor: Medical University of Gdańsk & Polish Lymphoma Research Group (PLRG), externally supported by Bristol Myeras Squibb Global; PI: prof. Andrea Gallamini, Nice, France)
PACIFIC-R: Real World First retrospective real-world data on Unresectable stage III NSCLC Patients treated with durvalumab within the Early Access Program after chemoradiotherapy. (Sponsor: AstraZeneca Global, UK).
MDT-BRIDGE: Non-randomized phase 2 GMA study of neo-adjuvant durvalumab + CT in early-stage NSCLC followed by surgery or CRT with adjuvant durvalumab (Sponsor: Astra Zeneca).
EORTC 2362-LCG-Stage III NSCLC SONAR: A prospective non-interventional cohort study in patients with Stage III NSCLC (EORTC Lung Cancer Group 2025)
PACIFIC-LECOMTE: ILD diagnosis and prediction through radiomics in stage 3 unresectable NSCLC (Sponsor: AstraZeneca).
APOLLO-11: Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research (Sponsor INT Milan, European Grant)

He has been or currently is the National Coordinator or Local PI of:

Local PI and Italian coordinator for PACIFIC-9 study: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Local PI: EORTC PrimaLUNG 1901-LCG: PRophylactic cerebral irradiation or active magnetic resonance imaging surveillance in small-cell lung cancer patients (sponsor: EORTC)
Local PI: MK-7684A-006/KEYVIBE-006: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006). Sponsor: Merck Sharp and Dome (MSD).
Local PI: The Impact of COVID-19 on NSCLC Treatment: A multi-site, international observational study to understand the impact of the COVID-19 pandemic on the treatment of patients with Stage III unresectable non-small cell lung cancer (NSCLC) (Sponsor AstraZeneca).